QURE
No price yet
Announcements
Nothing here yet
Daily updates
- uniQure shares fell after updated data from its Huntington's disease gene-therapy program, with analysts suggesting investors expected stronger durability at the four-year assessment supporting potential AMT-130 approval.Oct 4, 2026
- uniQure reported updated Phase 1/2 data for ifezuntirgene inilparvovec in Huntington’s disease, showing dose-dependent slowing of clinical decline.Sep 29, 2026
FDA designations
Nothing here yet
News
- uniQure reports additional data from ongoing Phase 1/2 studies of AMT-130 in Huntington’s disease showing continued slowing of disease progressionSep 29, 2026
- uniQure submitted a Biologics License Application for ifezuntirgene inilparvovec (AMT-130) for Huntington's diseaseSep 7, 2026
- uniQure announced plans to submit a BLA for AMT-130 in Huntington's diseaseJun 17, 2026
- uniQure announces positive topline results from pivotal Phase I/II study of AMT-130 in patients with Huntington's diseaseSep 24, 2025
- uniQure announces initial AMT-191 Phase I/IIa data showing sustained increases in α-Gal A enzyme activity in Fabry disease patientsSep 5, 2025